Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN HIVES RELIEF REDITAB versus CLARITIN D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN HIVES RELIEF REDITAB versus CLARITIN D.
CLARITIN HIVES RELIEF REDITAB vs CLARITIN-D
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Selective inverse agonist of peripheral histamine H1 receptors, inhibiting histamine release from mast cells and basophils.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1 receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
Relief of symptoms associated with seasonal and perennial allergic rhinitisTreatment of chronic idiopathic urticaria
Temporary relief of symptoms of seasonal allergic rhinitis (e.g., sneezing, runny nose, itchy/watery eyes)Temporary relief of nasal congestion due to common cold, hay fever, or upper respiratory allergies
10 mg orally once daily
One tablet (5 mg loratadine/120 mg pseudoephedrine sulfate) orally every 12 hours; do not exceed 2 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life of loratadine is 8.4 hours (range 3–20 hours); for its active metabolite descarboethoxyloratadine, it is 24.9 hours (range 8.8–45 hours). Clinical context: Steady-state concentrations are achieved by day 5.
Loratadine: 8-14 h (mean 11 h); desloratadine: 17-24 h (mean 21 h). Pseudoephedrine: 4-8 h (mean 6 h), prolonged in alkaline urine.
Primarily metabolized by CYP3A4 to descarboethoxyloratadine; also metabolized by CYP2D6 to a lesser extent.
Loratadine is extensively metabolized in the liver via CYP3A4 and CYP2D6 to its active metabolite descarboethoxyloratadine. Pseudoephedrine is partially metabolized in the liver by N-demethylation and undergoes renal excretion.
Primarily renal (approximately 40% as metabolites, <1% as unchanged drug) and fecal (approximately 40% as metabolites).
Loratadine: 40% renal (metabolites), ~40% fecal; desloratadine: 33% renal, 66% fecal. Pseudoephedrine: 70-90% renal unchanged, 1-2% biliary.
Loratadine: 97–99% bound to albumin and alpha-1-acid glycoprotein. Descarboethoxyloratadine: 73–76% bound.
Loratadine: 97-99% (albumin, alpha-1-acid glycoprotein); desloratadine: 82-87%; pseudoephedrine: negligible (<5%).
Loratadine: approximately 120 L/kg (high, indicating extensive tissue distribution). Descarboethoxyloratadine: 704 L/kg.
Loratadine: 120 L/kg (extensive tissue distribution); desloratadine: 15-20 L/kg; pseudoephedrine: 2-3 L/kg (distributes into body water).
Oral bioavailability of loratadine is 40–50% due to first-pass metabolism. The orally disintegrating tablet is bioequivalent to conventional tablets.
Loratadine: ~40% (high first-pass metabolism); pseudoephedrine: ~100% (oral); desloratadine: ~40-50% (oral).
No adjustment required. CrCl 10-50 mL/min: use with caution; CrCl <10 mL/min: contraindicated if anuria.
For GFR 30-50 mL/min: administer every 24 hours. For GFR <30 mL/min: contraindicated due to risk of pseudoephedrine accumulation.
Child-Pugh A: no adjustment; Child-Pugh B or C: start 5 mg orally once daily.
Child-Pugh Class A: no adjustment. Child-Pugh Class B or C: administer every 24 hours or consider alternative therapy.
6-12 years: 5 mg orally once daily; >12 years: 10 mg orally once daily. Weight-based: not typically required.
Children <12 years: not recommended due to fixed-dose combination. Children ≥12 years: same as adult dose.
No specific adjustment; monitor for dizziness or sedation.
Elderly patients (≥65 years): use with caution due to increased sensitivity to pseudoephedrine (e.g., CNS stimulation, hypertension); consider starting with lower dose or alternative therapy.
None
Not available.
Severe hepatic impairment (dose adjustment required); renal impairment (CrCl <30 mL/min, starting dose of 10 mg every other day); use with caution in patients with history of seizures; may impair ability to drive or operate machinery.
Severe hypertension or coronary artery disease; increased intraocular pressure; glaucoma; prostatic hypertrophy; diabetes mellitus; thyroid disease; use in patients with renal or hepatic impairment; avoid use with MAOIs or within 14 days of stopping MAOIs; risk of cardiovascular events including stroke and arrhythmias.
Hypersensitivity to loratadine or any component of the formulation; severe hepatic impairment (Child-Pugh class C) without dose adjustment.
Hypersensitivity to loratadine, pseudoephedrine, or any component; narrow-angle glaucoma; severe hypertension; severe coronary artery disease; concurrent use or recent use of MAOIs (within 14 days); urinary retention; patients with severe hepatic impairment.
Data Pending Review
Data Pending Review
No significant food interactions. Grapefruit juice may slightly increase absorption but is clinically irrelevant. Avoid alcohol to minimize sedation risk.
Avoid concurrent consumption of alcohol or caffeine-containing beverages (coffee, tea, cola) as they may exacerbate stimulant effects. Taking with food may reduce gastrointestinal irritation. Avoid high-tyramine foods (aged cheese, cured meats) if also taking MAOIs (contraindicated due to hypertensive crisis risk).
FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects; no adequate human studies in pregnant women. Potential for minor malformations not established. Risk to fetus considered low based on limited data.
First trimester: No evidence of teratogenicity in animal studies; limited human data. Second/third trimester: Risk of premature labor, low birth weight, and neonatal withdrawal with chronic high-dose decongestant use.
Loratadine is excreted into human breast milk in small amounts (M/P ratio approximately 1.2). Not expected to cause adverse effects in nursing infants at usual doses. Caution recommended due to lack of long-term safety data.
Loratadine (antihistamine) and pseudoephedrine (decongestant) both excreted in breast milk. M/P ratio for loratadine is approximately 1.1; pseudoephedrine M/P ratio is approximately 2.6. Potential for irritability and decreased milk supply due to pseudoephedrine. Use with caution, preferably immediate-release loratadine alone.
No dose adjustment required. Pharmacokinetics of loratadine are not significantly altered in pregnancy based on limited studies. Standard adult dose of 10 mg once daily is used.
No standard dose adjustments for pregnancy. Pharmacokinetic changes (increased renal blood flow, decreased plasma protein binding) may alter drug clearance but no specific dose recommendations due to lack of data. Use lowest effective dose for shortest duration.
Category C
Category C
Loratadine is a long-acting non-sedating antihistamine for chronic urticaria and allergic rhinitis. Onset within 1-3 hours, duration 24 hours. Avoid in severe hepatic impairment (Child-Pugh >10). No QT prolongation at therapeutic doses.
CLARITIN-D combines loratadine (antihistamine) and pseudoephedrine (decongestant). Use with caution in hypertension, hyperthyroidism, and prostate hypertrophy. Avoid in severe coronary artery disease. Monitor for insomnia and nervousness. Onset of action within 1-3 hours, duration 12 hours. Extended-release formulation must not be crushed or chewed.
Take once daily with or without food.Do not exceed 1 tablet daily.May cause drowsiness in rare cases; avoid driving if affected.Not for immediate relief of hives; takes up to 3 hours for effect.Stop use and consult doctor if hives persist >6 weeks or worsen.
Take exactly as directed; do not exceed 2 tablets in 24 hours.Swallow whole; do not crush or chew extended-release tablets.Avoid alcohol; may increase drowsiness or dizziness.Contact your doctor if symptoms persist beyond 7 days or with fever.Do not use with other decongestants or antihistamines without consulting a physician.May cause insomnia; take last dose at least 4-6 hours before bedtime.Inform your doctor if you have high blood pressure, heart disease, or prostate issues.